Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 3Sarcoma 1Recurrence 1Neoplasm Metastasis 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 4tucatinib 3Capecitabine 3fludarabine 2Radiotherapy 2Magnetic Resonance Spectroscopy 2Cyclophosphamide 2sapanisertib 1pertuzumab 1patritumab deruxtecan 1omburtamab I-131 1gadopiclenol 1gadobutrol 1fludarabine phosphate 1avelumab 1aldesleukin 1Spinal Puncture 1Specimen Handling 1Nivolumab 1Methotrexate 1Mesna 1Interleukin-2 1Blood Specimen Collection 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × AZD1390 × 1 year × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡